Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Core Viewpoint - Resverlogix Corp. is currently under a management cease trade order application due to delays in completing its annual financial statements audit, which has resulted in a default on the filing deadline [1][2]. Group 1: Management Cease Trade Order (MCTO) Update - The application for the MCTO is still under review by the Alberta Securities Commission (ASC), with no decision made yet [1]. - The company has defaulted on the March 31, 2026 deadline for filing its annual audited financial statements and related documents due to the auditor's inability to complete the audit on time [1][2]. - The company is working with the auditor to resolve initial delays and is optimistic about completing the annual filings by April 10, 2026, although this cannot be assured [2]. Group 2: Implications of the Default - If the MCTO is granted, the CEO and CFO will be prohibited from trading the company's securities, while the general public can continue trading the company's common shares [3]. - The company is committed to satisfying the alternative information guidelines under NP 12-203, including issuing bi-weekly default status reports until the annual filings are completed [4]. Group 3: Company Background - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company specializing in epigenetics and aims to develop first-in-class therapies for chronic diseases [6]. - The company is focused on its lead epigenetic candidate, apabetalone, for treating cardiovascular disease and related conditions [7]. - Resverlogix's common shares are traded on the Toronto Stock Exchange under the ticker RVX [8].

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it intends to change its corporate name from “Algernon Health Inc.” to “Grey Matters Health Inc.” (the “Name Change”). The Company has reserved the new name and new symbol “GREY” with the Canadian Securities Exchange (the “CSE”). The new symbols for the OTCQB and Frankfurt exchange will be provided shortl ...

Core Viewpoint - Richtech Robotics is facing a securities class action lawsuit following a significant drop in its stock price after a report indicated that Microsoft denied a commercial partnership with the company [1][6]. Group 1: Lawsuit Details - The lawsuit aims to represent investors who acquired Richtech securities between January 27, 2026, and January 29, 2026, after the stock price fell over 20% due to the news from Hunterbrook Media [1][2]. - Hagens Berman, a national shareholder rights law firm, has initiated an investigation into the claims that Richtech violated federal securities laws [2]. Group 2: Company Announcements and Market Reaction - On January 27, 2026, Richtech announced a collaboration with Microsoft, which initially led to a 30% increase in its stock price due to perceived commercial potential [4]. - The following day, Richtech disclosed a dilutive private placement of 8.5 million Class B common shares, raising concerns about the timing and implications of the announcement [5]. - On January 29, 2026, Hunterbrook Media reported that Microsoft characterized the engagement as a standard customer program without commercial elements, leading to a rapid decline in Richtech's stock price [6]. Group 3: Allegations and Investigative Focus - The lawsuit alleges that Richtech misled investors regarding the nature of its relationship with Microsoft, suggesting a more substantial partnership than existed [5][7]. - Hagens Berman's investigation is focused on whether Richtech intentionally misled investors to facilitate the equity raise and if this constitutes a new form of "AI washing" [7].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Direct Digital Holdings reported a 28% increase in buy-side revenue for Q4 2025, while consolidated revenue decreased by 7% compared to Q4 2024 [1][3] - The company is focusing on enhancing its buy-side presence and has launched Ignition+, an AI-enabled programmatic media solution aimed at large enterprise clients [2][3] - Operating expenses were reduced by 12% in Q4 2025 compared to Q4 2024 and by 18% for the full year 2025 compared to 2024 [1][3] Q4 2025 Financial Results - Buy-side advertising segment served approximately 195 customers, generating $8.2 million in revenue, a 28% increase from $6.4 million in Q4 2024 [3] - Consolidated revenue for Q4 2025 was $8.4 million, down from $9.1 million in Q4 2024 [3] - Sell-side advertising segment revenue fell to $0.2 million from $2.7 million in Q4 2024, attributed to a decrease in impression inventory [3] - Gross profit was $2.3 million, representing 27% of revenue, compared to 32% in Q4 2024 [3] - Operating expenses totaled $6.7 million, down from $7.7 million in Q4 2024 [3] Full Year 2025 Financial Results - Total revenue for 2025 was $34.7 million, a 44% decrease from $62.3 million in 2024 [9] - Buy-side advertising revenue increased by 10% to $29.4 million from $26.6 million in 2024 [9] - Sell-side advertising revenue plummeted by 85% to $5.3 million from $35.7 million in 2024 [9] - Gross profit for the year was $10.4 million, or 30% of revenue, compared to 28% in 2024 [9] - Operating expenses decreased by 18% to $25.2 million from $30.6 million in 2024 [9] Strategic Developments - The company issued $25 million in Series A Convertible Preferred Stock in Q3 2025 and an additional $10 million in Q4 2025 to strengthen its capital structure [5][6] - A 55-to-1 reverse stock split was implemented to regain compliance with Nasdaq listing requirements [7] - The company aims to streamline operations and enhance efficiency through a strategic pivot towards buy-side growth [2][3] Management Commentary - The CEO expressed optimism about the company's growth driven by new customers and demand from new verticals [2] - The CFO highlighted efforts to strengthen the balance sheet and improve access to capital, positioning the company for better results in 2026 [8]

Core Viewpoint - The article discusses the trading strategies around biotech stocks, particularly focusing on events such as trial results and NDA/BLA approvals, while also covering companies regulated by the FDA [1]. Group 1: Trading Strategies - The emphasis is on trading biotech stocks based on significant events that can influence stock prices, such as trial results and regulatory approvals [1]. Group 2: Industry Focus - The article highlights the importance of understanding the regulatory environment, particularly the role of the FDA in the biotech industry, which can impact company performance and stock valuations [1].

March 31 (Reuters) - Greek stocks will return to MSCI's developed markets index in May 2027, the index provider said on Tuesday, marking the latest step in the Greek economy's normalization after a debt crisis that began in 2009. Greece set to rejoin MSCI developed markets index in 2027 | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv An aerial view of the city as the sun sets in Thessaloniki, Greece, July 10, 2022. REUTERS/Ilan Rosenberg/File Photo Pu ...

Core Viewpoint - The UK's drug cost-effectiveness watchdog, NICE, has recommended Novo Nordisk's Wegovy for reducing the risk of serious heart problems or strokes in obese or overweight adults, marking it as the first GLP-1 drug endorsed for this purpose [1][2]. Group 1: Drug Approval and Recommendations - Wegovy, at a 2.4-milligram dose, will be available through the National Health Service (NHS) following NICE's recommendation [2]. - The drug will be integrated into existing cardiovascular treatment pathways, allowing healthcare providers to consider it alongside standard therapies for secondary prevention of heart issues in overweight or obese adults [2]. Group 2: Clinical Evidence - NICE's recommendation was based on a study involving over 17,600 participants, demonstrating that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo [3]. - In 2024, Wegovy received UK regulatory approval to reduce the risk of major cardiovascular events in obese or overweight adults with preexisting heart disease, although initial access was limited to patients paying out-of-pocket [3]. Group 3: Market Context - Approximately one in four adults in the UK is estimated to be living with obesity, highlighting a significant market for weight-loss and cardiovascular drugs [4]. - Eli Lilly, a competitor, has raised the UK list price for its weight-loss drug Mounjaro by up to 170% last year, indicating competitive pricing pressures in the market [5].

Market Performance - The final trading day of March saw significant gains, with the Dow up +1125 points (+2.49%), the S&P 500 up +104 points (+2.91%), and the Nasdaq up +795 points (+3.83%) [1] - The small-cap Russell 2000 also increased by +82 points (+3.40%) [1] Economic Indicators - The Job Openings and Labor Turnover Survey (JOLTS) for February reported 6.88 million job openings, slightly below the projected 6.92 million, and down from a revised 7.2 million in January [4] - The Chicago Business Barometer for March decreased to 52.8, below the estimated 55.1, following a 12-month high of 57.7 in February, but remains above the growth threshold of 50 [5] - Consumer Confidence for March unexpectedly rose to 91.8, surpassing the estimated 87.5 and the revised February figure of 91.0, indicating improved consumer sentiment [6] Company Earnings - NIKE (NKE) reported earnings of +$0.35 per share, exceeding the expected +$0.29, with revenues of $11.28 billion, also above the consensus of $11.23 billion, driven by strong performance in China [7] - RH (formerly Restoration Hardware) missed earnings expectations with $1.53 per share against the expected $2.21, and revenues of $843 million fell short of the $872.4 million forecast, leading to a significant reduction in revenue guidance for the current quarter [8]